Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

Nature Reviews Drug Discovery

Volumn 6, Issue 4, 2007, Pages 295-303

  Shaw, Leslie M ^a   Korecka, Magdalena ^a   Clark, Christopher M ^a   Lee, Virginia M Y ^a   Trojanowski, John Q ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 8 HYDROXYDEOXYGUANOSINE; ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BETA SECRETASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD59 ANTIGEN; COMPLEMENT COMPONENT C1Q; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE AMMONIA LIGASE; HOMOCYSTEINE; INTERLEUKIN 6 RECEPTOR; ISOPROSTANE; KALLIKREIN; MELANOTRANSFERRIN; NEUROFILAMENT PROTEIN; OXYSTEROL; PRESENILIN 1; PRESENILIN 2; PROTEIN S100B; SULFATIDE; TAU PROTEIN; TRANSFERRIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; DEGENERATIVE DISEASE; DIAGNOSTIC VALUE; DRUG MONITORING; DRUG RESPONSE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; NEUROIMAGING; NEUROPATHOLOGY; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN URINE LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; TAUOPATHY; VALIDATION PROCESS;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DRUG MONITORING; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 33947729229     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2176     Document Type: Review

References (93)

1. Dobson, C. M. Protein folding and misfolding. Nature 426, 884-890 (2003).
2. Forman, M. S., Trojanowski, J. Q. & Lee, V. M.-Y. Neurodegenerative diseases: A decade of discoveries paves the way for therapeutic breakthroughs. Nature Med. 10, 1055-1063 (2004).
3. Selkoe, D. J. Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases. Nature Cell Biol. 6, 1054-1061 (2004).
4. Skovronsky, D. M., Lee, V. M.-Y. & Trojanowski, J. Q. Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. Mech. Dis. 1, 151-170 (2006).
5. Cookson, M. R. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74, 29-52 (2005).
6. Dawson, T. M. & Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819-822 (2003).
7. Forman, M. S., Lee, V. M.-Y. & Trojanowski, J. Q. Nosology of Parkinson's disease: Looking for the way out of a quackmire. Neuron 47, 479-482 (2005).
8. Greenamyre, J. T. & Hastings, T. G. Parkinson's - divergent causes, convergent mechanisms. Science 304, 1120-1122 (2004).
9. Savitt, J. M., Dawson, V. L. & Dawson, T. M. Diagnosis and treatment of Parkinson disease: Molecules to medicine. J. Clin. Invest. 116, 1744-1754 (2006).
10. Forman, M. S. et al. Frontotemporal dementia: Clinicopathological correlations. Ann. Neurol. 59, 952-962 (2006).
11. McKeith, I. G. et al. Dementia with Lewy bodies: Diagnosis and management: Third report of the DLB Consortium. Neurology 65, 1863-1872 (2005).
12. Cairns, N. J., Lee, V. M.-Y. & Trojanowski, J. Q. The cytoskeleton in neurodegenerative diseases. J. Pathol. 204, 438-449 (2004).
13. Lee, V. M.-Y., Kenyon, T. K. & Trojanowski, J. Q. Transgenic animal models of tauopathies. Biochem. Biophys. Acta 1739, 251-259 (2005).
14. Fillit, H. M. & Refolo, L. M. Advancing drug discovery for Alzheimer's disease. Curr. Alzheimer Res 2, 105-109 (2005).
15. Zhang, B. et al. Microtubule binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a murine neurodegenerative tauopathy model. Proc. Natl Acad. Sci. USA 102, 227-231 (2005).
16. Michaelis, M. L. et al. β-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. J. Pharmacol. Exp. Ther. 312, 659-668 (2005).
17. Rice, A. et al. Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ. J. Med. Chem. 48, 832-838 (2005).
18. Dickey, C. A. et al. Development of a high throughput drug screening assay for the detection of changes in tau levels: Proof of concept with HSP90 inhibitors. Curr. Alzheimer Res. 2, 231-239 (2005).
19. Pickhardt, M. et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J. Biol. Chem. 280, 3628-3635 (2005).
20. Pickhardt, M. et al. Screening for inhibitors of tau polymerization. Curr. Alzheimer Res. 2, 219-226 (2005).
21. Noble, W. et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA 102, 6990-6995 (2005).
22. Phiel, C. J., Wilson, C. A., Lee, V. M.-Y. & Klein. P. S. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 423, 435-439 (2003).
23. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus report of the Working Group on Biological Markers of Alzheimer's Disease. Neurobiol. Aging 19, 109-116 (1998).
24. Frank, R. A. et al. Biological markers for therapeutic trials in Alzheimer's disase - Proceedings of The Biological measures Working Group: NIA Initiative on Neuroimaging in Alzheimer's Disease. Neurobiol. Aging 24, 521-536 (2003).
25. Blennow, K., de Leon, M. J. & Zetterberg, H. Alzheimer's disease. Lancet 368, 387-403 (2006).
26. Blennow, K. & Hampel, H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2, 605-613 (2003).
27. Clark, C. M. et al. Biochemical biomarkers of late-life dementia. Alzheimers Dement 2, 287-293 (2006).
28. Hansson, O. et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol. 5, 228-234 (2006).
29. de Leon, M. J. et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging 27, 394-401 (2006).
30. Thal, L. J. et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20, 6-15 (2006).
31. Mueller, S. G. et al. The Alzheimer's Disease Neuroimaging Initiative. Neuroimaging Clin. N. Am. 15, 869-877 (2005).
32. Clarke R., Smith D., Jobst D. M. & Refsum H. Folate, vitamin B12, and serum homocysteine levels in confirmed Alzheimer Disease. Arch. Neurol. 55, 1449-1455 (1998).
33. Seshadri S. et al. Plasma homocysteine as a risk factor for dementia and Alzheimers Disease. N. Engl. J. Med. 346, 476-483 (2002).
34. Saunders A. M. et al. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467-1472 (1993).
35. Hsiung G-Y. R., Sadovnick A. D. & Feldman H. Apolipoprotein E e4 genotype as a risk factor for cognitive decline and dementia: Data from the Canadian Study of Health and Aging. Can. Med. Assoc. J. 171, 863-867 (2004).
36. Clark, C. M. et al. Cerebrospinal fluid tau and β-amyloid: How well do these biomarkers reflect autopsy-confirmed dementia diagnoses. Arch. Neurol. 60, 1696-1702 (2003).
37. Ibach, B. et al. Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol. Aging 27, 1202-1211 (2006).
38. Grossman, M. et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann. Neurol. 57, 721-729 (2005).
39. Neumann, M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133 (2006).
40. Baker, M. et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916-919 (2006).
41. Cruts, M. et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920-924 (2006).
42. Tokuda, T. et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162-166 (2006).
43. Fagan, A. M. et al. Cerebropspinal fluid tau/Aβ42 predicts cognitive decline in nondemented older adults. Arch. Neurol. 8 Jan 2007 (doi:10.1001/archneur.64.3.noc60123).
44. Castano, E. M., Roher, A. E., Esh, C. L., Kokjohn, T. A. & Beach, T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol. Res. 28, 155-163 (2006).
45. Hu, Y., Malone, J. P., Fagan, A. M., Townsend, R. R. & Holtzman, D. M. Comparative proteomic analysis of intra- and inter-individual variation in human cerebrospinal fluid. Mol. Cell. Proteomics 4, 2000-2009 (2005).
46. Zhang, J. et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis. 7, 125-133 (2005).
47. Bateman, R. J., Wen, G., Morris, J. C. & Holtzman, D. M. Fluctuations of CSF amyloid b levels: Implications for a diagnostic and therapeutic biomarker. Neurol. (in the press).
48. Xu, S. & Gaskin, F. Increased incidence of anti-β-amyloid autoantibodies secreted by Epstein-Barr virus transformed β cell lines from patients with Alzheimer's disease. Mech. Ageing Dev. 94, 213-222 (1997).
49. Du, Y. et al. Reduced CSF levels of amyloid-β peptide antibody in Alzheimer's disease. Neurology 57, 801-805 (2001).
50. Abraham, C. R., Selkoe D. J. & Potter, H. Immunochemical identification of serine protease inhibitor α-1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52, 487-501 (1988).
51. Lanzrein, A. S. et al. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: IL 1β, IL 6, IL 1 receptor antagonist, TNFα, the soluble TNF receptors I and II, and α1-antichymotrypsin. Alzheimer Dis. Assoc. Disord. 12, 215-227 (1998).
52. Licastro, F., Morini, M. C., Polazzi, E. & Davis, L. J., Increased serum α 1 antichymotrypsin in patients with probable Alzheimer's disease: An acute phase reactant without the peripheral acute phase response. J. Neuroimmunol. 57, 71-75 (1995).
53. Licastro, F. et al. Increased plasma levels of IL 1, IL 6 and α-1-antichymotrypsin in patients with Alzheimer's disease: Peripheral inflammation or signals from the brain? J. Neuroimmunol. 103, 97-102 (2000).
54. Pirttila, T., Mehta, P. D., Frey H. & Wisniewski, H. M., α1 antichymotrypsin, and IL 1β are not increased in CSF or serum in Alzheimer's disease. Neurobiol. Aging 15, 313-317 (1994).
55. Henriksson, T. et al. Analysis and quantitation of the β-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay. J. Neurochem. 56, 1037-1042 (1991).
56. Palmert, M. R. et al. Soluble derivatives of the β amyloid protein precursor in cerebrospinal fluid: Alterations in normal aging and in Alzheimer's disease. Neurology 40, 1028-1034 (1990).
57. Sennvik, K. et al. Levels of α- and β-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 278, 169-172 (2000).
58. Van Nostrand, W. E. et al. Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc. Natl Acad. Sci. USA 89, 2551-2555 (1992).
59. Baskin, F., Rosenberg, R. N., Iyer, L., Hynan L. & Cullum, C. M. Platelet APP isoform ratios correlate with declining cognition in AD. Neurology 54, 1907-1909 (2000).
60. Di Luca, M. et al. Differential level of platelet amyloid β precursor protein isoforms: An early marker for Alzheimer disease. Arch. Neurol. 55, 1195-2000 (1998).
61. Padovani, A. et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch. Neurol. 59, 71-75 (2002).
62. Colciaghi, F. et al. Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 62, 498-501 (2004).
63. Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421 (2000).
64. Webster, S. et al. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging 18, 415-421 (1997).
65. Schmidt, R. et al.Early inflammation and dementia: A 25 year follow-up of the Honolulu-Asia aging study. Ann. Neurol. 52, 168-174 (2002).
66. Licastro, F. et al. α-1-antichymotrypsin and oxidative stress in the peripheral blood from patients with probable Alzheimer disease: A short-term longitudinal study. Alzheimer Dis. Assoc. Disord. 15, 51-55 (2001).
67. Webster, S. & Rogers, J. Relative efficacies of amyloid β peptide (Aβ) binding proteins in Aβ aggregation. J. Neurosci. Res. 46, 58-66 (1996).
68. Smyth, M. D. et al. Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state. Neurobiol. Aging 15, 609-614 (1994).
69. Gabbita, S. P., Lovell M. A. & Markesbery, W. R. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J. Neurochem. 71, 2034-2040 (1998).
70. Lovell M. A. & Markesbery, W. R. Ratio of 8 hydroxyguanine in intact DNA to free 8 hydroxyguanine is increased in the Alzheimer disease ventricular cerebrospinal fluid. Arch. Neurol. 58, 392-396 (2001).
71. Tumani, H., Shen, G., Peter J. B. & Bruck, W. Glutamine synthetase in cerebrospinal fluid, serum, and brain: A diagnostic marker for Alzheimer disease? Arch. Neurol. 56, 1241-1246 (1999).
72. Takahashi, M., Stanton, E., Moreno J. I. & Jackowski, G. Immunoassay for serum glutamine synthetase in serum: Development, reference values, and preliminary study in dementias. Clin. Chem. 48, 375-378 (2002).
73. Wallin, A., Blennow K. & Rosengren, L. E. Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. Dementia 7, 267-272 (1996).
74. Mecocci, P. et al. Serum anti-GFAP and anti S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia. J. Neuroimmunol. 57, 165-170 (1995).
75. Tanaka, J. et al. Enzyme-linked immunosorbent assay for human autobody to glial fibrillary acidic protein: Higher titer of the antibody is detected in serum of patients with Alzheimer's disease. Acta Neurol. Scand. 80, 554-560 (1989).
76. Terryberry, J. W., Thor G. & Peter, J. B. Autoantibodies in neurodegenerative diseases: Antigen-specific frequencies and intrathecal analysis. Neurobiol. Aging 19, 205-216 (1998).
77. Hampel, H. et al. Discriminant power of combined cerebrospinal fluid tau protein and soluble gp130 in the diagnosis of Alzheimer's disease. Brain Res. 823, 104-112 (1999).
78. Diamandis, E. P., Yousef, G. M., Petraki C. & Soosaipillai, A. R. Human kallikrein 6 as a biomarker of Alzheimer's disease. Clin. Biochem. 33, 663-667 (2000).
79. Zighetti, M. L. Chantarangkul, V., Tripodi, A., Mannucci P. M. & Cattaneo, M. Determination of total homocysteine in plasma: Comparison of the Abbott IMx immunoassay with high performance liquid chromatography. Haematologica 87, 89-94 (2002).
80. Kennard, M. L., Feldman, H., Yamada T. & Jefferies, W. A., Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nature Med. 2, 1230-1235 (1996).
81. Feldman, H. et al. Serum p97 levels as an aid to identifying Alzheimer's disease. J. Alzheimer Dis. 3, 507-516 (2001).
82. Kim, D. K. et al. Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease. Neuropsychopharmacology 25, 84-90 (2001).
83. Sjogren, M. et al. Neurofilament protein in cerebrospinal fluid: A marker of white matter changes. J. Neurosci. Res. 66, 510-516 (2001).
84. Sjogren, M. et al.Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 54, 1960-1964 (2000).
85. Hu, Y. Y. et al. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci. Lett. 320, 156-160 (2002).
86. Tohgi, H. et al. Alterations of 3 nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci. Lett. 269, 53-54 (1999).
87. Hensley, K. et al. Electrochemical analysis of protein nitrotyrosine and dityrosien in the Alzheimer brain indicates region-specific accumulation. J. Neurosci. 18, 8126-8132 (1998).
88. Hartmann, T. Cholesterol, A-β and Alzheimer's disease. Trends Neurosci. 24 (Suppl. 11), S45-S48 (2001).
89. Holtzman, D. M., Fagan A. M. & Han, X. CSF sulfatide levels: A possible biomarker for Alzheimer's disease at the earliest clinical stages. Neurology 58 (Suppl. 3), A361 (2002).
90. Han, X., Holtzman, D. M., McKeel, D. W., Kelly J. & Morris, J. C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: Potential role in disease pathogenesis. J. Neurochem. 82, 809-818 (2002).
91. Masliah, E. The role of synaptic proteins in Alzheimer's disease. Ann. NY Acad. Sci. 924, 68-75 (2000).
92. Giasson, B, I., Lee, V. M-Y., Ischiropoulos H. & Trojanowski, J. Q. The relationship between oxidative/ nitrative stress and pathological inclusions in Alzheimer's and Parkinson's disease. Free Radic. Biol. Med. 32, 1264-1275 (2002).
93. Sheng, J. G. et al. Human brain S100β and S100β mRNA expression increases with age: Pathogenic implications for Alzheimer's disease. Neurobiol. Aging 17, 359-363 (1996).